Literature DB >> 36147620

The Virulence Index: A Metric for Quantitative Analysis of Phage Virulence.

Zachary J Storms1, Matthew R Teel1, Kevin Mercurio1, Dominic Sauvageau1.   

Abstract

Background: One of the main challenges in developing phage therapy and manufacturing phage products is the reliable evaluation of their efficacy, performance, and quality. Since phage virulence is intrinsically difficult to fully capture, researchers have turned to rapid but partially inadequate methods for its evaluation. Materials and
Methods: This study demonstrates a standardized quantitative method to assess phage virulence based on three parameters: the virulence index (VP )-quantifying the virulence of a phage against a host, the local virulence (vi )-assessing killing potential at given multiplicities of infection (MOIs), and MV50 -the MOI at which the phage achieves 50% of its maximum theoretical virulence. This was shown through comparative analysis of the virulence of phages T4, T5, and T7.
Results: Under the conditions tested, phage T7 displayed the highest virulence, followed by phage T4 and, finally, by phage T5. The impact of parameters such as temperature and medium composition on virulence was shown for each phage. The use of the method to evaluate the virulence of combinations of phages-for example, for cocktail formulation-is also shown with phages T5 and T7. Conclusions: The method presented provides a platform for high-throughput quantitative assessment of phage virulence and quality control of phage products. It can also be applied to phage screening, evaluation of phage strains, phage mutants, infection conditions and/or the susceptibility of host strains, and the formulation of phage cocktails. Copyright 2020, Mary Ann Liebert, Inc., publishers.

Entities:  

Keywords:  bacterial reduction curve; bacteriophage infection; comparative virulence; high-throughput analysis; quality control; virulence quantification

Year:  2020        PMID: 36147620      PMCID: PMC9041455          DOI: 10.1089/phage.2019.0001

Source DB:  PubMed          Journal:  Phage (New Rochelle)        ISSN: 2641-6530


  46 in total

1.  The phage therapy paradigm: prêt-à-porter or sur-mesure?

Authors:  Jean-Paul Pirnay; Daniel De Vos; Gilbert Verbeken; Maia Merabishvili; Nina Chanishvili; Mario Vaneechoutte; Martin Zizi; Geert Laire; Rob Lavigne; Isabelle Huys; Guy Van den Mooter; Angus Buckling; Laurent Debarbieux; Flavie Pouillot; Joana Azeredo; Elisabeth Kutter; Alain Dublanchet; Andrzej Górski; Revaz Adamia
Journal:  Pharm Res       Date:  2010-11-10       Impact factor: 4.200

2.  Virulent mutants of phage P22. II. Physiological analysis of P22 virB-3 and its component mutations.

Authors:  M J Bronson; M Levine
Journal:  Virology       Date:  1972-03       Impact factor: 3.616

3.  In vitro design of a novel lytic bacteriophage cocktail with therapeutic potential against organisms causing diabetic foot infections.

Authors:  João J Mendes; Clara Leandro; Carla Mottola; Raquel Barbosa; Filipa A Silva; Manuela Oliveira; Cristina L Vilela; José Melo-Cristino; Andrzej Górski; Madalena Pimentel; Carlos São-José; Patrícia Cavaco-Silva; Miguel Garcia
Journal:  J Med Microbiol       Date:  2014-05-28       Impact factor: 2.472

Review 4.  The estimation of the basic reproduction number for infectious diseases.

Authors:  K Dietz
Journal:  Stat Methods Med Res       Date:  1993       Impact factor: 3.021

5.  Evaluation of a lytic bacteriophage, Φ st1, for biocontrol of Salmonella enterica serovar Typhimurium in chickens.

Authors:  Chuan Loo Wong; Chin Chin Sieo; Wen Siang Tan; Norhani Abdullah; Mohd Hair-Bejo; Jalila Abu; Yin Wan Ho
Journal:  Int J Food Microbiol       Date:  2013-12-07       Impact factor: 5.277

6.  Phage-bacterium war on polymeric surfaces: can surface-anchored bacteriophages eliminate microbial infections?

Authors:  Heather A Pearson; Gyan S Sahukhal; Mohamed O Elasri; Marek W Urban
Journal:  Biomacromolecules       Date:  2013-04-16       Impact factor: 6.988

7.  Romulus and Remus, two phage isolates representing a distinct clade within the Twortlikevirus genus, display suitable properties for phage therapy applications.

Authors:  Katrien Vandersteegen; Andrew M Kropinski; John H E Nash; Jean-Paul Noben; Katleen Hermans; Rob Lavigne
Journal:  J Virol       Date:  2013-01-09       Impact factor: 5.103

8.  Host range and lytic capability of four bacteriophages against bovine and clinical human isolates of Shiga toxin-producing Escherichia coli O157:H7.

Authors:  Y D Niu; R P Johnson; Y Xu; T A McAllister; R Sharma; M Louie; K Stanford
Journal:  J Appl Microbiol       Date:  2009-03-16       Impact factor: 3.772

9.  Phage fitness may help predict phage therapy efficacy.

Authors:  Heather M Lindberg; Kurt A McKean; Ing-Nang Wang
Journal:  Bacteriophage       Date:  2014-12-15

10.  Design of a Broad-Range Bacteriophage Cocktail That Reduces Pseudomonas aeruginosa Biofilms and Treats Acute Infections in Two Animal Models.

Authors:  Francesca Forti; Dwayne R Roach; Marco Cafora; Maria E Pasini; David S Horner; Ersilia V Fiscarelli; Martina Rossitto; Lisa Cariani; Federica Briani; Laurent Debarbieux; Daniela Ghisotti
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.